GENTAMICIN SULFATE
AMINOGLYCOSIDES, PARENTERAL·SEPSIS CAUSED BY ENTEROBACTER·+63
EUGIA US LLC
Indication
Synergy for Staphylococcus skin and skin structure infection
The phrase "Synergy for Staphylococcus skin and skin structure infection" is not a recognized, standardized medical condition or formal FDA drug indication on its own. Read more about Synergy for Staphylococcus skin and skin structure infection
12 drugs 11 manufacturers
Drugs that treat it
Common Synergy for Staphylococcus skin and skin structure infection therapies.
GENTAMICIN SULFATE
AMINOGLYCOSIDES, PARENTERAL·SEPSIS CAUSED BY ENTEROBACTER·+63
Hikma Pharmaceuticals USA
GENTAMICIN SULFATE
AMINOGLYCOSIDES, PARENTERAL·SEPSIS CAUSED BY ENTEROBACTER·+63
FRESENIUS KABI
Filter & compare in the drug finder →Opens the drug finder with Synergy for Staphylococcus skin and skin structure infection preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonThe phrase "Synergy for Staphylococcus skin and skin structure infection" is not a recognized, standardized medical condition or formal FDA drug indication on its own.
Rather, it describes a therapeutic strategy—antimicrobial synergy via combination therapy—applied to staphylococcal acute bacterial skin and skin structure infections (ABSSSIs) or complicated skin and soft tissue infections.
In clinical medicine, staphylococcal skin and skin structure infections involve bacterial invasion of the cutaneous and subcutaneous layers by species such as *Staphylococcus aureus*, typically manifesting as cellulitis, purulent cutaneous abscesses, or wound infections characterized by localized erythema, edema, warmth, and tissue necrosis.
Pharmacologic synergy denotes the combined use of two or more antimicrobial agents to achieve enhanced bactericidal activity, tissue penetration, or overcoming of bacterial resistance mechanisms in severe, recalcitrant, or biofilm-associated infections.
- fda.gov
The phrase "Synergy for Staphylococcus skin and skin structure infection" is not a recognized, standardized medical condition or formal FDA drug indication on its own Rather, it describes a therapeutic strategy—antimicrobial synergy via combination therapy—applied to staphylococcal acute bacterial skin and skin structure infections (ABSSSIs) or complicated skin and soft tissue infections In clinical medicine, staphylococcal skin and skin structure infections involve bacterial invasion of the cut...
- fda.gov
The phrase "Synergy for Staphylococcus skin and skin structure infection" is not a recognized, standardized medical condition or formal FDA drug indication on its own
- nih.gov
Rather, it describes a therapeutic strategy—antimicrobial synergy via combination therapy—applied to staphylococcal acute bacterial skin and skin structure infections (ABSSSIs) or complicated skin and soft tissue infections Pharmacologic synergy denotes the combined use of two or more antimicrobial agents to achieve enhanced bactericidal activity, tissue penetration, or overcoming of bacterial resistance mechanisms in severe, recalcitrant, or biofilm-associated infections
- contagionlive.com
In clinical medicine, staphylococcal skin and skin structure infections involve bacterial invasion of the cutaneous and subcutaneous layers by species such as *Staphylococcus aureus*, typically manifesting as cellulitis, purulent cutaneous abscesses, or wound infections characterized by localized erythema, edema, warmth, and tissue necrosis
- acs.org
Pharmacologic synergy denotes the combined use of two or more antimicrobial agents to achieve enhanced bactericidal activity, tissue penetration, or overcoming of bacterial resistance mechanisms in severe, recalcitrant, or biofilm-associated infections
- nih.gov
Pharmacologic synergy denotes the combined use of two or more antimicrobial agents to achieve enhanced bactericidal activity, tissue penetration, or overcoming of bacterial resistance mechanisms in severe, recalcitrant, or biofilm-associated infections
Personalize your experience
Follow Synergy for Staphylococcus skin and skin structure infection and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.